KNect365 is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Waking up market to US obstructive sleep apnea epidemic

With an estimated 30 million sufferers of obstructive sleep apnea, estimated to cost the US economy about $162 billion, there is an urgent need to find an acceptable solution. While CPAP is considered 100% effective, only 30% of patients prescribed the device use it routinely. During the 2018 Biotech Showcase, RespireRx president and CEO James Manuso explained to Scrip how the company is repurposing a D9-THC, small molecule cannabinoid receptor agonist, already on the market for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy, that can be taken orally an hour before sleep. Phase IIb studies demonstrated the drug’s effectiveness. Manuso is now looking for partners and financiers to commercialize the drug.

Get the latest news as it happens.